Gentamicin Sulfate

Manufacturer
Physicians Total Care, Inc.
Effective date
2010-06-07
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 20:08:40

Label at a glance#

ProductGentamicin Sulfate
Active ingredientGENTAMICIN SULFATE
Label structure10 sections

Indications and uses

Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Ge...

Dosage and administration

A small amount of Gentamicin Sulfate Ointment should be applied gently to the lesions three or four times daily. The area treated may be covered with a gauze dressing if desired. In impetigo contagiosa, the crusts should be removed before application of gentamicin sulfate to permit maximum contact between the antibiotic and the infection. Care should be exercised to avoid further contamination of the infected skin...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

For Dermatologic Use Only Not For Ophthalmic Use

DESCRIPTION

DESCRIPTION SECTION

Gentamicin Sulfate Ointment is a wide spectrum antibiotic preparation for topical administration. Each gram contains 1.0 mg of Gentamicin in a base of White Petrolatum with Methylparaben and Propylparaben as preservatives.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Gentamicin sulfate is a wide spectrum antibiotic that provides highly effective topical treatment in primary and secondary bacterial infections of the skin. Gentamicin Sulfate Ointment may clear infections that have not responded to treatment with other topical antibiotic agents. In primary skin infections such as impetigo contagiosa, treatment 3 or 4 times daily with Gentamicin Sulfate Ointment usually clears the lesions promptly. In secondary infections, Gentamicin Sulfate Ointment aids in the treatment of the underlying dermatoses by controlling the infection. Bacteria susceptible to the action of gentamicin sulfate include sensitive strains of Streptococci (group A beta-hemolytic, alpha-hemolytic), Staphylococcus aureus (coagulase positive, coagulase negative, and some penicillinase-producing strains), and the gram-negative bacteria, Pseudomonas aeruginosa, Aerobacter aerogenes, Escherichia coli, Proteus vulgaris, and Kiebsiella pneumoniae.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This drug product is contraindicated in individuals with a history of sensitivity to any of its components.

PRECAUTIONS

PRECAUTIONS SECTION

The use of topical antibiotics occasionally allows overgrowth of nonsusceptible organisms, including fungi. If this condition occurs, or if irritation, sensitization or superinfection develops, treatment with gentamicin sulfate should be discontinued and appropriate therapy instituted.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

In patients with dermatoses treated with gentamicin sulfate, irritation (erythema and pruritis) that did not usually require discontinuance of treatment has been reported in a small percentage of cases. There was no evidence of irritation or sensitization, however, in any of these patients patch-tested subsequently with gentamicin sulfate on normal skin. Possible photosensitization has been reported in several patients but could not be elicited in these patients by reapplication of gentamicin sulfate followed by exposure to ultraviolet radiation.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

A small amount of Gentamicin Sulfate Ointment should be applied gently to the lesions three or four times daily. The area treated may be covered with a gauze dressing if desired. In impetigo contagiosa, the crusts should be removed before application of gentamicin sulfate to permit maximum contact between the antibiotic and the infection. Care should be exercised to avoid further contamination of the infected skin. Infected stasis ulcers have responded well to treatment with gentamicin sulfate under gelatin packing.

HOW SUPPLIED

HOW SUPPLIED SECTION

Gentamicin Sulfate Ointment USP, 0.1% is supplied in 15 gram tubes NDC 54868-6126-0.

Store at controlled room temperature 15°-30°C (59°-86°F).

E FOUGERA & CO
A division of Nycomed US Inc.
Melville, New York 11747 USA

I27815C
R2/08
#292



Relabeling of "Additional Barcode" by:
Physicians Total Care, Inc.
Tulsa, OK       74146

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

GENTAMICIN
SULFATE OINTMENT
UPS, 0.1%

Rx only

FOR EXTERNAL USE ONLY.
NOT FOR OPHTHALMIC USE.

Each gram contains 1.0 mg of
Gentamicin in a base of White
Petrolatum with Methylparaben
and Propylparaben as preservatives.

NET WT 15 grams

image of package labelimage of package label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
310465gentamicin sulfate 0.1 % Topical OintmentPSN2
310465gentamicin 0.001 MG/MG Topical OintmentSCD2
310465gentamicin (as gentamicin sulfate) 0.1 % Topical OintmentSY2
310465gentamicin sulfate 0.001 MG/MG Topical OintmentSY2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
GENTAMICIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
3b7b3a7a-635f-32a3-0c6c-7ad028e3de91Product name220250107
43025f0d-698c-68da-cec9-ea4261a7ef7aProduct name220250107
d3946667-8212-d1f2-67e1-5643a329bb56Product name220200403
4ce5dce5-e8a7-e4f6-0059-b527e4307477Product name220190501
48b05f5d-d2fc-45ab-76e8-3cb5bd44890dProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
54868-6126-02019-09-24C16284748780-19350213a-3fb0-c013-e053-90daa90a139378d87bc5-be86-4429-8ca3-e0a883108f9b

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
54868-6126-0Gentamicin Sulfate15 g in 1 TUBEOINTMENT152

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
54868-6126GENTAMICIN SULFATE OINTMENT [PHYSICIANS TOTAL CARE, INC.]21 package rows20100611_78d87bc5-be86-4429-8ca3-e0a883108f9b.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
54868-6126-0GM - Gram54868-61267c4253e9-6710-4aba-9505-eae1ad2e561e12015-02-02

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
GENTAMICIN SULFATEACTIVE INGREDIENT8X7386QRLV2
GENTAMICINACTIVE MOIETYT6Z9V48IKG2
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9T2
PETROLATUMINACTIVE INGREDIENT4T6H12BN9U2
PROPYLPARABENINACTIVE INGREDIENTZ8IX2SC1OH2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54868-612654868-6126-0
0168-0078

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 3 · 165 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
PETROLATUMPETROLATUM4T6H12BN9USOAP / TOPICAL0.85 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TTABLET, COATED / ORAL0.8 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHTABLET, CHEWABLE / ORAL0.14 mgExact identifier — unii candidate
68 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UAEROSOL, FOAM / TOPICAL7.9 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION/ DROPS / OPHTHALMIC0.05 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UCREAM, AUGMENTED / TOPICAL26 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCREAM / TOPICAL6 mgExact identifier — unii candidate
68 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT / VAGINAL4084 mgExact identifier — unii candidate
18 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHTABLET, COATED / ORAL0.8 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / TOPICAL216 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TOINTMENT / OPHTHALMIC0.05 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TFILM / BUCCAL1 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCONCENTRATE / ORAL12 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSYRUP / ORAL40 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSHAMPOO, SUSPENSION / TOPICAL0.15 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS15 mgExact identifier — unii candidate
79 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UCAPSULE, EXTENDED RELEASE / ORAL0.07 mgExact identifier — unii candidate
18 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / OPHTHALMIC0.02 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / RECTAL0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / NASAL250 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / SOFT TISSUE0.15 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TEMULSION / TOPICAL0.2 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSYSTEM / TOPICAL21 mgExact identifier — unii candidate
68 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9USPONGE / TOPICALNAExact identifier — unii candidate
18 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TDROPS / ORAL1 mg/1mlExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHDROPS / OPHTHALMIC0.01 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR0.4 mgExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHJELLY / TOPICAL180 mgExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSUSPENSION / AURICULAR (OTIC)NAExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSUSPENSION, EXTENDED RELEASE / ORAL40 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / EPIDURAL1 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION, SOLUTION / INTRAVENOUS5 mgExact identifier — unii candidate
68 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UTABLET / ORAL3.5 mgExact identifier — unii candidate
18 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCREAM / TOPICAL3000 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TAEROSOL, FOAM / TOPICAL0.16 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSYRUP / ORAL81 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHTABLET, EXTENDED RELEASE / ORAL0.12 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TJELLY / NASAL250 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TPOWDER, FOR SUSPENSION / ORAL75 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION / INTRALESIONAL0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION / INFILTRATION0.35 mgExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / TOPICAL24 mgExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHAEROSOL, FOAM / TOPICAL0.04 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHLIQUID / TOPICAL0.1 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / IRRIGATION2 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCREAM / VAGINAL22 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TGEL / VAGINAL8 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHENEMA / RECTAL0.02 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TELIXIR / ORAL800 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSUPPOSITORY / VAGINALNAExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TDROPS / AURICULAR (OTIC)0.01 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / INTRAMUSCULAR0.13 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCREAM / VAGINAL3 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSUPPOSITORY / VAGINALNAExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSPRAY / TOPICAL0.8 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCAPSULE, EXTENDED RELEASE / ORAL0.22 mgExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHOINTMENT / OPHTHALMIC0.01 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION, SUSPENSION / SUBCUTANEOUS0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCAPSULE / ORAL1 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / IONTOPHORESIS0.1 %w/vExact identifier — unii candidate
79 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062533-001GENTAMICIN SULFATEGENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A062533-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-0584e616aacf4f…
2026-08-18 06:07:402026-07A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-0531067a03dcf5…
2025-08-23 18:47 UTC2025-08A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-056a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-0503ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-052680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-055bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-0579d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-051e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-058072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-055c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-055d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-054b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-0574a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-0587673890dc5c…
2021-03-12 10:30 UTC2021-03A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-055aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-058869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-053f01610625f2…
2019-09-15 20:21 UTC2019-09A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05b00525d2431f…
2019-07-19 19:46 UTC2019-07A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-056a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-051c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-059b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-053f0d92c62455…
2023-05-13 08:27 UTC2023-05A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05053a50430f4f…
2023-01-26 05:58 UTC2023-01A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-053bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-053a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062533-001GENTAMICIN SULFATEEQ 0.1% BASEOINTMENT / TOPICALAT1984-10-05f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A062533-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A062533-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062533-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062533-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A062533-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062533-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062533-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062533-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062533-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062533-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062533-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062533-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062533-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062533-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062533-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062533-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062533-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062533-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062533-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062533-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062533-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062533-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062533-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A062533-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062533-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062533-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062533-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A062533-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A062533-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062533-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062533-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062533-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062533-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062533-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062533-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062533-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A062533-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A062533-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062533-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062533-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
a706be2f-5593-485d-8791-b7aa923e2dfd78d87bc5-be86-4429-8ca3-e0a883108f9b2010-06-07Adverse reactionsExact identifier
spl id: a706be2f-5593-485d-8791-b7aa923e2dfd
spl set id: 78d87bc5-be86-4429-8ca3-e0a883108f9b

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.